comparemela.com

Latest Breaking News On - Nasdaq pcrx - Page 2 : comparemela.com

AIA Group Ltd Buys 11,198 Shares of Pacira BioSciences, Inc (NASDAQ:PCRX)

AIA Group Ltd increased its stake in shares of Pacira BioSciences, Inc. (NASDAQ:PCRX – Free Report) by 21.1% during the 3rd quarter, HoldingsChannel.com reports. The firm owned 64,391 shares of the company’s stock after purchasing an additional 11,198 shares during the quarter. AIA Group Ltd’s holdings in Pacira BioSciences were worth $1,976,000 at the end […]

Pacira BioSciences (NASDAQ:PCRX) Shares Gap Up to $31 47

Pacira BioSciences, Inc. (NASDAQ:PCRX – Get Free Report)’s stock price gapped up before the market opened on Wednesday . The stock had previously closed at $31.47, but opened at $32.16. Pacira BioSciences shares last traded at $32.72, with a volume of 52,474 shares trading hands. Analyst Upgrades and Downgrades A number of research firms have […]

Pacira BioSciences, Inc (NASDAQ:PCRX) Stock Position Raised by Rock Springs Capital Management LP

Rock Springs Capital Management LP raised its position in shares of Pacira BioSciences, Inc. (NASDAQ:PCRX – Free Report) by 0.2% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,035,000 shares of the company’s stock after purchasing an additional 2,400 shares during […]

Pacira BioSciences, Inc (NASDAQ:PCRX) Given Consensus Rating of Moderate Buy by Analysts

Shares of Pacira BioSciences, Inc. (NASDAQ:PCRX – Get Free Report) have earned a consensus recommendation of “Moderate Buy” from the nine analysts that are covering the stock, Marketbeat Ratings reports. One investment analyst has rated the stock with a hold recommendation and eight have issued a buy recommendation on the company. The average 1-year target […]

Pacira BioSciences, Inc (NASDAQ:PCRX) Given Average Rating of Moderate Buy by Brokerages

Pacira BioSciences, Inc. (NASDAQ:PCRX – Get Free Report) has earned an average rating of “Moderate Buy” from the nine research firms that are presently covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a hold rating and eight have issued a buy rating on the company. The average twelve-month target […]

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.